(CLNN) Clene Inc. Business Model Canvas Research

Clene Inc. relies on contract research organizations to run trial operations, manage data, and coordinate sites, which lets a clinical-stage company scale several studies at once without hiring every team in-house. This matters because Clene is still funding R&D from a thin revenue base, so CROs help keep fixed costs lower while it advances complex clinical programs.

• Run multicenter trial operations

• Manage data and site coordination

• Scale concurrent studies faster

Clene’s key partners are manufacturing and supply vendors that make CSN drug substance, formulation, packaging, and study supply. This matters across its 4-program pipeline — CNM-Au8, CNM-AgZn17, CNM-ZnAg, and CNM-PtAu7 — because each needs tight control on quality, batch consistency, and timing to keep trials moving.

• Stable supply keeps studies on schedule
• Controlled batches support product consistency
• Vendor delays can disrupt clinical continuity

For Clene, reliable CMO and CPO partners are not support roles; they are a core risk control for execution.

Clene Inc. advances four nanocrystal assets: CNM-Au8, CNM-AgZn17, CNM-ZnAg, and CNM-PtAu7. Pipeline breadth is a core activity because it expands Clene beyond neurology into infectious disease, immune support, wound recovery, and oncology.

• Four assets reduce single-program risk.
• Broader targets widen market reach.
• More shots improve long-term optionality.

Clene also sells dietary supplements, including rMetx and KHC46, so it has a non-drug revenue path while its ALS and MS candidates move through development. Public filings do not break out supplement sales as a separate line item, but this activity helps keep the Company in market now, not just at the clinical stage.

• Non-drug sales support near-term presence
• rMetx and KHC46 widen the product mix
• Clinical pipeline still drives long-term value

Clene Inc.’s pipeline compounds are a core internal asset: CNM-Au8, CNM-AgZn17, CNM-ZnAg, and CNM-PtAu7 extend the platform into separate therapeutic paths, so the company is not tied to one program. The value is strategic, not just scientific: one platform can create multiple shots on goal.

• 4 compounds in the platform
• Multiple therapeutic categories
• Internal IP and pipeline value

Clene Inc.’s scientific and clinical team is a core resource because it needs 4 skill sets at once: nanotechnology, neurology, infectious disease, and clinical development. That mix is what lets Clene design studies, read the data correctly, and support its Salt Lake City, Utah base with specialized expertise.

• 4 key expertise areas
• Study design and data readout
• Salt Lake City, Utah headquarters

CNM-AgZn17 and CNM-ZnAg extend Clene beyond neurology into infection targets, with broad antibacterial and antiviral potential, including COVID-19-related use cases. That matters in a huge market: WHO says antimicrobial resistance caused 1.27 million deaths in 2019, so even early-stage assets can open a large non-neurology growth path.

• Broad-spectrum antibacterial and antiviral reach
• COVID-19-related applications
• Moves Clene into infection markets

rMetx and KHC46 give Clene Inc. a consumer-facing supplement line while therapeutic programs move through development, so the brand can keep selling today. They also reinforce Clene Inc.’s nanotechnology story, helping build awareness around its platform even before any drug approval.

• Commercial supplements, not just pipeline assets
• Supports near-term consumer revenue
• Extends nanotechnology-based brand identity

Clene Inc. keeps patient community communication central because people with ALS and other serious neurologic diseases often seek trial access and science updates; ALS affects about 30,000 people in the U.S. and sees roughly 5,000 new diagnoses each year. Clear outreach helps build awareness, support enrollment, and sustain trust in rare-disease groups.

• Drives trial awareness
• Supports ALS participation
• Builds trust with patients

Clene Inc.’s rMetX and KHC46 customer relationships should be direct, fast, and product-led: buyers need clear support on use, dosing, and ordering, not clinical care. That service layer builds trust, drives repeat purchase, and lowers friction when products are sold through consumer channels.

• Direct product guidance
• Service, not clinical, support
• Repeat purchase and trust

Healthcare provider networks are a key channel for Clene Inc., because ALS and Parkinson’s care usually starts with specialists, then moves through referral networks and care centers. That matters if a lead program reaches commercialization: the U.S. has about 30,000 people living with ALS and over 1 million with Parkinson’s, so adoption will depend on neurologists and high-volume centers.

• Specialists drive diagnosis and treatment
• Referrals shape patient access
• Care centers support rollout

rMetx and KHC46 fit consumer-facing routes, so retail shelves and online storefronts can reach buyers faster than prescription channels. For dietary supplements, direct-to-consumer and e-commerce access matters because these products do not need the same clinic-based gatekeeping as therapeutics.

• Use retail for broad reach
• Use online for fast access
• Match channels to supplement demand

Clene Inc. serves infection-control users: CNM-AgZn17 is aimed at infectious diseases and wound recovery, while CNM-ZnAg is positioned as broad-spectrum antiviral and antibacterial support, including COVID-19-related use. The core buyers are care settings and patients where infection pressure is high and faster healing can cut length of stay and resource use.

• Infectious disease treatment settings
• Wound care and recovery patients
• Hospitals and clinics needing infection control
• Antiviral and antibacterial use cases

Clene Inc.’s supplement consumers are separate from its clinical-trial patients: rMetx and KHC46 are sold as dietary supplements for buyers seeking zinc-silver or gold-based formulas. This segment targets retail wellness users, while Clene’s clinical programs serve ALS and MS study populations.

• Dietary-supplement buyers, not trial patients
• rMetx and KHC46: zinc-silver or gold-based use
• Distinct from Clene’s clinical pipeline

Clene Inc. must keep paying for submission prep, validated quality systems, and constant FDA/agency contact, and those costs climb fast as programs move from preclinical work into late-stage trials and filing work. For context, the FDA’s FY2025 standard human drug application user fee was about $4.3 million, before adding CMC, QA, and inspection readiness costs; compliance also applies to any supplement activity under GMP rules.

• Submission work drives recurring spend.
• Late-stage trials raise QA and CMC costs.
• Drug and supplement compliance both matter.

Clene Inc.’s general and administrative overhead is driven by its Salt Lake City headquarters, where finance, legal, HR, and investor relations keep the public-company platform running. These costs are recurring and support SEC reporting, audit, compliance, and board support, so they stay in place even when R&D spending shifts.

• HQ shared services: finance, legal, HR
• Public-company costs: audit, SEC, IR
• Supports the operating platform

Clene Inc. can generate milestone revenue from biopharma partnerships when it reaches clinical or regulatory steps in ALS or other indications. This stream is event-driven, so cash comes only if development advances and partner contracts trigger payments.

• Milestone-based, not recurring
• Tied to ALS trial progress
• Depends on partner agreements

Clene Inc. still has no approved product revenue, so the main upside is approval-driven commercialization of CNM-Au8 and any follow-on pipeline asset. That makes the company’s value highly dependent on pivotal study success, because an approved therapy can shift sales from one-time trial funding to recurring product revenue.

In practical terms, the revenue stream is binary: if late-stage data support FDA or other market approval, Clene Inc. can target a larger, longer-lived commercial base; if not, revenue stays tied to research and partnership income.